No single blood test confirms Kawasaki disease. Diagnosis combines fever history, examination, inflammatory markers, supporting laboratory findings, and echocardiography—persistent fever in a child needs prompt assessment, not a wait for every classic symptom.
اهم ڳالهيون
- تشخيص requires clinical assessment; no individual Kawasaki disease blood test can reliably confirm or exclude the condition.
- Persistent fever lasting 5 days warrants prompt assessment for Kawasaki disease, but a child who looks seriously unwell needs care sooner.
- سوزش جا نشان of CRP ≥30 mg/L or ESR ≥40 mm/hour support further evaluation in the American Heart Association incomplete-disease pathway.
- Incomplete Kawasaki disease may occur with only 2–3 classic features; infants can have prolonged fever with very few visible signs.
- پليٽليٽس ≥450 × 10⁹/L after day 7 are a supporting finding; normal platelets during the first week do not rule out Kawasaki disease.
- Supporting results include albumin ≤30 g/L, anemia for age, elevated ALT, WBC ≥15 × 10⁹/L, and urine ≥10 white cells per high-power field.
- ايڪو ڪارڊيوگرافي evaluates coronary arteries and heart function; a normal early scan does not exclude Kawasaki disease.
- علاج جو وقت matters: hospital treatment usually includes intravenous immunoglobulin, ideally within the first 10 illness days, without waiting for every symptom.
Can a Kawasaki disease blood test confirm the diagnosis?
No single Kawasaki disease blood test confirms the diagnosis. Blood tests measure inflammation and organ responses, while clinicians identify the illness from fever, examination findings, and heart imaging; a child with fever for 5 days needs prompt assessment even when the full symptom pattern is absent.
Kawasaki disease is a childhood vasculitis that can affect the coronary arteries. The 2017 American Heart Association statement estimates coronary artery aneurysms in approximately 25% of untreated cases; that figure describes untreated disease, not every child with prolonged fever or an elevated CRP result (McCrindle et al., 2017). Most affected children are younger than 5 years, although older children can develop it.
An abnormal inflammatory marker is evidence of an immune response, not a disease identity. A CRP of 80 mg/L can occur in Kawasaki disease, a bacterial illness, or another inflammatory condition, so the result cannot settle the diagnosis by itself. Equally, a report with only 1 flagged value may underestimate concern if the sample was collected early or interpreted against adult ranges.
Kantesti is an AI blood test analyzer that can explain CRP, CBC, and liver-test terminology without diagnosing Kawasaki disease. اسان جو pediatric interpretation safeguards explain why a 3-year-old's results cannot be read using adult assumptions. Information اسان جي اداري بابت identifies who provides this educational service; persistent fever still requires assessment by a clinician.
When should persistent fever in a child be assessed?
A child with fever lasting 5 days should receive prompt clinical assessment, including consideration of Kawasaki disease. Seek care earlier for serious illness, concerning symptoms, or a young infant; the diagnostic fever duration is not an instruction to remain at home until day 5.
A temperature of 38°C or higher in an infant younger than 3 months requires urgent medical assessment. At any age, difficulty breathing, unusual sleepiness, poor responsiveness, a non-blanching rash, marked dehydration, or signs of poor circulation warrant emergency care. These findings are not specific to Kawasaki disease; sepsis and other time-sensitive conditions must also be considered.
Fever responding temporarily to paracetamol does not exclude Kawasaki disease. A child may become more comfortable between temperature spikes while the underlying illness continues, and symptoms can appear on different days. Record when fever first began, actual temperature readings, medicines, urine output, and changes in eyes, lips, hands, or feet—not just whether the thermometer was normal once.
Infants younger than 6 months may have prolonged fever without the familiar rash-and-red-eye pattern. Unexplained fever lasting at least 7 days is a recognized trigger for incomplete-disease evaluation in the AHA pathway. Our sample preparation guidance is useful for planned testing, but a sick child should never wait for fasting, a convenient appointment, or a complete symptom checklist.
How is Kawasaki disease diagnosed from clinical signs?
Classic Kawasaki disease is usually diagnosed from fever lasting at least 5 days plus at least 4 of 5 principal clinical features. Clinicians can diagnose some strongly characteristic cases earlier; neither the fever count nor the symptom count replaces clinical judgment or urgent evaluation.
The 5 principal features are bilateral non-purulent conjunctival redness, mouth changes, a polymorphous rash, extremity changes, and cervical lymphadenopathy. Mouth changes include red or cracked lips and a strawberry tongue; hand and foot changes include redness or swelling. The lymph-node criterion is usually a cervical node at least 1.5 cm across, often on one side.
The clinical features do not have to occur simultaneously. A photograph of a rash from illness day 3 may remain diagnostically useful when the skin looks different on day 6, and a previous episode of swollen hands should not disappear from the history because swelling has improved. Peeling around the fingertips often occurs during weeks 2–3, too late to use as a reason to delay assessment.
Certain findings point toward alternative explanations rather than strengthening the classic Kawasaki pattern. Purulent eye discharge, prominent exudative tonsillitis, or discrete mouth ulcers deserve separate consideration, although no single finding resolves every case. Our laboratory marker reference guide explains test terminology; it cannot substitute for examining the 5 clinical feature groups or arranging appropriate imaging.
How do labs support incomplete Kawasaki disease?
Incomplete Kawasaki disease means a child has fewer classic features but enough clinical, laboratory, or echocardiographic evidence to warrant diagnosis and treatment. The AHA evaluation pathway considers children with fever for at least 5 days and 2–3 features, and certain infants with unexplained fever for at least 7 days.
CRP ≥30 mg/L or ESR ≥40 mm/hour supports proceeding through the AHA incomplete-disease evaluation pathway. When inflammation reaches either threshold, clinicians assess echocardiography and supplementary laboratory criteria rather than waiting for another visible symptom. The thresholds are decision supports for a compatible illness—not proof that Kawasaki disease is the cause (McCrindle et al., 2017).
The 6 supplementary laboratory criteria are albumin ≤30 g/L, anemia for age, elevated ALT, WBC ≥15 × 10⁹/L, platelets ≥450 × 10⁹/L after day 7, and urine ≥10 white cells per high-power field. In the appropriate clinical setting, at least 3 supplementary criteria or a positive echocardiogram can support treatment through the pathway. These are not independent points to count without reviewing competing diagnoses.
Fewer than 3 supplementary criteria does not create a permanent rule-out result. Persistent fever may require repeated examination, repeat laboratory testing, and imaging, particularly if the first evaluation occurred early. Systemic juvenile idiopathic arthritis is one possible alternative; our childhood arthritis laboratory guide explains why shared inflammatory findings do not make these conditions interchangeable.
What do CRP and ESR results mean in Kawasaki disease?
CRP and ESR support Kawasaki evaluation by showing systemic inflammation, but neither identifies its cause. In the AHA incomplete-disease pathway, CRP ≥30 mg/L or ESR ≥40 mm/hour is a threshold for further assessment, not a severity scale or a stand-alone indication for treatment.
CRP of 3 mg/dL equals 30 mg/L. This 10-fold unit difference can make identical results appear very different when families compare reports from different laboratories, while common CRP reference limits are around 5 mg/L but vary by method. Our WBC and CRP comparison explains why a high CRP and a less impressive white-cell count can coexist.
ESR is influenced by factors beyond the immediate inflammatory response, including anemia and circulating proteins. A result of 45 mm/hour is not directly comparable to CRP of 45 mg/L; the tests measure different processes and have different kinetics. When both markers are below the pathway thresholds, Kawasaki disease becomes less likely, but an early sample or a concerning clinical course still requires judgment.
High-sensitivity CRP measures the same protein as conventional CRP, but adult cardiovascular-risk categories do not apply to a febrile child. A value of 30 mg/L during illness should not be interpreted using an adult 1–3 mg/L cardiovascular-risk framework. Our hs-CRP interpretation guide explains that distinction; for acute pediatric illness, the clinical question is inflammation and its cause.
| سطح | حد | ان جو مطلب |
|---|---|---|
| CRP جي عام حوالياتي حد | Often <5 mg/L; laboratory-specific | A reference interval, not a Kawasaki exclusion threshold; early disease may require reassessment. |
| Incomplete-disease CRP trigger | ≥30 mg/L, equivalent to ≥3 mg/dL | Supports further AHA pathway evaluation when fever and clinical history are compatible. |
| Common ESR reference interval | Often approximately 0–20 mm/hour; age- and method-dependent | Use the reporting laboratory's pediatric interval; ESR is affected by anemia and proteins. |
| Incomplete-disease ESR trigger | ≥40 mm/hour | Supports further evaluation; neither confirms Kawasaki disease nor defines an emergency by itself. |
Which CBC findings support Kawasaki disease?
Kawasaki disease lab findings on a CBC can include neutrophil-predominant leukocytosis, anemia for age, and a later rise in platelets. WBC ≥15 × 10⁹/L and platelets ≥450 × 10⁹/L after day 7 are supplementary incomplete-disease criteria, but the illness day changes their meaning.
Platelets often rise during the second week rather than at the start of fever. A platelet count of 280 × 10⁹/L on illness day 4 therefore does not exclude Kawasaki disease, and waiting for thrombocytosis can delay care. Conversely, a count of 520 × 10⁹/L after day 7 supports the pattern but can also occur during recovery from other inflammatory illnesses.
Anemia in the incomplete-disease criteria is defined against the child's age, not a universal hemoglobin cutoff. For a hypothetical 3-year-old, hemoglobin of 9.8 g/dL would generally be low, but the cause could include inflammation, pre-existing iron deficiency, or both. WBC also needs age-specific context; our نيوٽروفلز جي حوالاتي حد بابت رهنمائي explains why pediatric differential counts differ from adult ones.
Low platelets can occur in severe Kawasaki presentations and should not be treated as reassuring. A febrile child with platelets of 90 × 10⁹/L, poor circulation, or worsening organ function needs urgent assessment for shock, sepsis, consumption, or macrophage activation. Platelet size indices and neutrophil-to-lymphocyte ratios remain contextual findings; they are not substitutes for the 6 established supplementary criteria.
Why do albumin and liver tests change?
Low albumin and elevated ALT can support incomplete Kawasaki disease because systemic inflammation affects protein distribution and liver function. Albumin ≤30 g/L is a defined supplementary criterion, while ALT is judged against the laboratory's pediatric upper reference limit rather than one universal Kawasaki cutoff.
Albumin of 3.0 g/dL equals 30 g/L. During acute illness, a low result can reflect reduced synthesis, increased vascular permeability, dilution, or protein loss—not simply poor dietary protein intake. Our سيرم پروٽين تشريح گائيڊ explains these mechanisms; nutritional advice alone would miss the clinical significance of low albumin combined with persistent fever.
An ALT result above the pediatric upper limit counts as supporting evidence, but its magnitude does not diagnose Kawasaki disease. For example, a hypothetical child with albumin 28 g/L and ALT 72 IU/L may meet 2 supplementary criteria if that ALT exceeds the local limit. The same combination can arise from other illnesses or medication effects, as our ALT اصطلاحن واري رهنمائي بيان ڪري ٿو.
Kantesti is an AI blood test interpretation platform that can explain why albumin 28 g/L and ALT 72 IU/L require clinical context. اسان جو AI ٽيڪنالاجي وضاحت describes the interpretation workflow, not a validated Kawasaki diagnostic test. Growing children can also have relatively high alkaline phosphatase from bone activity; that finding is not interchangeable with the ALT criterion.
Can urine tests and sodium support the evaluation?
Urine white cells can support incomplete Kawasaki evaluation, while electrolyte changes help assess illness severity and alternative causes. Urine ≥10 white cells per high-power field is a supplementary criterion; low sodium is a possible associated finding but is not one of the 6 AHA supplementary laboratory criteria.
Sterile pyuria means urine white cells are present without a demonstrated bacterial cause on an appropriately collected culture. Kawasaki disease can produce this pattern, but a child with urine white cells still needs assessment for urinary infection. A urine dipstick alone cannot establish sterile pyuria; our پيشاب جي تلڇٽ جي تشريح واري رهنمائي distinguishes microscopy findings from dipstick screening results.
A report of 10 white cells per high-power field cannot be directly equated with an automated result of 10 cells/µL. Instruments, specimen preparation, and counting methods differ, so clinicians may need the laboratory's conversion or interpretive guidance. Collection quality also matters: contamination can introduce cells, whereas prior antibiotics can reduce culture yield without explaining the entire fever pattern.
Serum sodium below 135 mmol/L is generally classified as hyponatremia, but its cause must be assessed separately. Acute inflammation, fluid intake, gastrointestinal losses, and altered water regulation can all contribute; the number is not a Kawasaki confirmation test. Our اليڪٽرولائيٽ پئٽرن گائيڊ explains why sodium 130 mmol/L with neurological symptoms is a different problem from an isolated mildly low value.
What does an echocardiogram add to the diagnosis?
Echocardiography assesses coronary artery dimensions, heart function, and other cardiac findings that blood tests cannot show. A coronary artery Z-score ≥2.5 can support Kawasaki diagnosis in the incomplete-disease pathway, but a normal early echocardiogram does not exclude the illness or justify delaying indicated treatment.
A coronary Z-score compares artery size with the expected size for a child's body surface area. A raw measurement such as 3 mm therefore has different implications in a small infant and a much larger child. The 2024 AHA statement emphasizes coronary assessment and risk-based management; the number should be interpreted with the measurement method and clinical setting (Jone et al., 2024).
A positive echocardiogram in the AHA incomplete-disease pathway can include a coronary aneurysm or a qualifying coronary Z-score. It can also involve at least 3 suggestive findings: decreased left-ventricular function, mitral regurgitation, pericardial effusion, or left anterior descending/right coronary Z-scores of 2 to less than 2.5. This is specialist image interpretation, not a checklist parents should apply to a brief scan summary.
Troponin and BNP or NT-proBNP may help evaluate cardiac involvement but do not replace echocardiography. A normal troponin on 1 sample cannot show that the coronary arteries are unaffected, and an elevated BNP can have several explanations. Our myocarditis laboratory guide explains the distinction between evidence of heart-muscle involvement and the separate question of coronary artery changes.
How do clinicians distinguish Kawasaki disease from mimics?
Clinicians distinguish Kawasaki disease from other causes of fever by combining the illness timeline, examination, targeted infection testing, laboratory patterns, and heart imaging. MIS-C, bacterial infections, adenovirus, scarlet fever, and systemic inflammatory disorders can overlap; a CRP result of 80 mg/L cannot separate them reliably.
MIS-C often follows SARS-CoV-2 infection by approximately 2–6 weeks and frequently affects older children than classic Kawasaki disease. Prominent gastrointestinal symptoms, shock, lymphopenia, relatively low platelets, and ventricular dysfunction may favor MIS-C, but overlap is substantial. A positive SARS-CoV-2 antibody result alone does not settle the distinction because previous infection or vaccination can affect interpretation.
Procalcitonin can rise in Kawasaki disease and should not automatically be treated as proof of a bacterial cause. Clinicians assess cultures, examination, organ function, and the broader trajectory before deciding what an elevated result means. Our پروڪالسٽونن جي تشريح واري رهنمائي explains why 1 biomarker cannot safely decide between sepsis, Kawasaki disease, or another inflammatory syndrome.
Finding a respiratory virus does not necessarily exclude coexisting Kawasaki disease. A hypothetical child with 6 days of fever, characteristic mouth changes, swollen feet, and an adenovirus-positive swab still needs a complete clinical assessment rather than automatic dismissal of the other findings. Travel, medication exposure, urinary symptoms, and recurrent fever patterns guide additional testing; there is no universal panel that rules out every mimic.
Why do illness day and repeat testing change the picture?
Kawasaki laboratory findings evolve, so the illness day and treatment history are part of every result's meaning. A normal platelet count early in the first week can become elevated later, while intravenous immunoglobulin can raise ESR independently of ongoing inflammation and make post-treatment ESR misleading.
A changing CBC can strengthen suspicion without making the first sample wrong. For example, a hypothetical child might have WBC 13 × 10⁹/L and platelets 280 × 10⁹/L on day 4, then platelets 480 × 10⁹/L and albumin 29 g/L on day 7. Clinicians should not postpone a concerning assessment until those later findings appear; our ليبارٽري ٽائم لائن گائيڊ explains evolving results.
ESR should not be used as the main measure of response after intravenous immunoglobulin. The infused proteins can increase sedimentation, so an ESR of 70 mm/hour after treatment does not necessarily mean treatment failure. Fever, clinical recovery, CRP trends, and cardiac assessment are more useful in context; the 2017 AHA statement specifically describes this post-infusion limitation (McCrindle et al., 2017).
Kantesti can help explain serial reports, but a trend graph cannot determine whether a child needs retreatment. Record the sample date, illness day, infusion completion time, and laboratory units alongside each value; comparing 2 results without that information can produce a false impression of deterioration. Immunoglobulin can also complicate some antibody tests through passive antibody transfer, so the treating team needs the infusion history.
Why should treatment not wait for every symptom?
Treatment should begin promptly when Kawasaki disease is diagnosed, including incomplete disease, rather than waiting for every classic feature. Standard initial hospital treatment includes intravenous immunoglobulin at 2 g/kg, generally within the first 10 illness days; later treatment may still be indicated when fever or inflammation persists.
The 10-day treatment window is a target for timely care, not a reason to delay until day 10. The ACR/Vasculitis Foundation guideline recommends prompt treatment of incomplete Kawasaki disease once diagnosed, rather than waiting for the child to satisfy classic criteria (Gorelik et al., 2022). For a hypothetical 12-kg child, 2 g/kg represents 24 g of immunoglobulin administered under hospital supervision.
Aspirin treatment in Kawasaki disease requires a pediatric specialist's prescription and monitoring. Acute regimens vary internationally, including 30–50 or 80–100 mg/kg/day, followed in many cases by antiplatelet dosing of 3–5 mg/kg/day; families should not start, stop, or calculate treatment themselves. Our aspirin toxicity guidance explains why a prescribed Kawasaki regimen is not ordinary home fever treatment.
Approximately 10–20% of patients have persistent or recurrent fever after initial immunoglobulin treatment. Fever at least 36 hours after completion of the infusion is a commonly used threshold for IVIG resistance, after other causes are considered. Additional treatment may include corticosteroids or other specialist therapies; infants younger than 6 months and children with coronary Z-scores ≥2.5 can need particular attention, but risk scores do not perform equally across populations.
What follow-up is needed when blood tests improve?
Improving CRP and CBC results do not prove that coronary artery risk has resolved. Follow-up is based on clinical recovery and echocardiographic findings, including the largest coronary Z-score recorded; children with coronary aneurysms need a different surveillance plan from children whose coronary studies remain normal.
Uncomplicated follow-up often includes echocardiography around 1–2 weeks and 4–6 weeks after treatment, but the schedule is individualized. The 2024 AHA statement supports risk-based assessment, and normal early studies can affect whether further routine imaging adds value (Jone et al., 2024). Persistent coronary changes, poor visualization, recurrent symptoms, or an abnormal initial study can require a different timetable.
A platelet count that remains elevated during recovery is not, by itself, proof of treatment failure. A hypothetical count of 600 × 10⁹/L in week 2 may fit the expected illness phase even when fever has stopped and CRP is falling, but symptoms and cardiac findings still govern management. Our پوسٽ-هاسپيٽل ليبارٽري تبديليون guide explains why normalization is not simultaneous across all markers.
High-dose immunoglobulin can affect the timing of certain live vaccines. After IVIG 2 g/kg, measles- and varicella-containing vaccines are commonly deferred for 11 months under immunization guidance, with exceptions assessed by the child's team and local schedule. Ask for a written plan covering vaccines, medicines, activity, repeat imaging, and which symptoms require reassessment; coronary follow-up should not be replaced by an apparently reassuring laboratory report.
How can AI explanations be used safely during evaluation?
AI explanations can help families understand laboratory language, but they cannot confirm Kawasaki disease, assess a child's circulation, or interpret coronary imaging independently. With fever lasting 5 days—or concerning symptoms sooner—clinical assessment takes priority over uploading reports, comparing reference ranges, or obtaining another automated interpretation.
Kantesti is an AI lab test interpretation service that can explain what CRP 30 mg/L or platelets 450 × 10⁹/L mean in a report. Those numbers are not sufficient to decide whether a child has Kawasaki disease, and an explanation cannot replace documenting illness day, examination findings, or an echocardiogram. Our ذميوار AI جا اصول describe why interpretation must remain separate from urgent pediatric decision-making.
A useful review packet combines at least 3 types of information: the fever timeline, complete laboratory reports, and the treating team's assessment. Preserve units, pediatric reference intervals, medication dates, and imaging conclusions rather than sharing only red flags or screenshots of isolated values. Our medical validation documentation describes evaluation standards and limitations; technical performance should not be read as condition-specific proof of diagnostic safety.
Kantesti's research publications listed below describe platform evaluation and aggregate report analysis, not a Kawasaki diagnostic assay. The Clinical Validation Framework v2.0 and Global Health Report 2026 are hosted on Zenodo, and their DOI identifiers establish persistent records rather than peer-review status. Neither publication should be interpreted as establishing sensitivity or specificity for incomplete Kawasaki disease; clinical recommendations here rely on the 2017 and 2024 AHA statements and the ACR/Vasculitis Foundation guideline.
اڪثر پڇيا ويندڙ سوال
ڇا ڪو رت جو ٽيسٽ ڪاواساڪي بيماري جي تصديق ڪري ٿو؟
ڪا هڪ رت جي جاچ ڪاواساڪي بيماري جي تصديق نٿي ڪري. طبيب بخار جي تاريخ، معائني دوران ملندڙ نشانين، سوزش جي نشانين، اضافي ليبارٽري نتيجن ۽ ايڪوڪارڊيوگرافي کي گڏائي جائزو وٺندا آهن. CRP ≥30 mg/L يا ESR ≥40 mm/hour، AHA جي نامڪمل بيماري واري طريقيڪار ۾ وڌيڪ جائزي جي ضرورت جي حمايت ڪري ٿو، پر سوزش جو سبب سڃاڻي نٿو. ڪنهن هڪ نتيجي جو نارمل هجڻ، خاص ڪري بيماري جي شروعاتي مرحلي ۾، هن حالت کي محفوظ نموني رد نٿو ڪري سگهي.
ڇا ڪنهن ٻار کي ڪاواساڪي جي بيماري جون سڀئي علامتون ظاهر ٿيڻ کان سواءِ به اها بيماري ٿي سگهي ٿي؟
0 ٻار ۾ ڪاواساڪي جي نامڪمل بيماري ٿي سگهي ٿي، ڀلي ان ۾ سڀئي 5 مکيه ڪلينڪي نشانيون موجود نه هجن. AHA جي رهنمائي ۾ اهي ٻار شامل آهن جن کي گهٽ ۾ گهٽ 5 ڏينهن بخار هجي ۽ 2–3 نشانيون هجن، ۽ ڪجهه اهڙا ننڍڙا ٻار به جن کي گهٽ ۾ گهٽ 7 ڏينهن تائين بنا وضاحت جي بخار هجي. مددگار ليبارٽري غيرمعموليتون يا ڪورونري شريانيون جا نتيجا تشخيص ۽ علاج جو جواز فراهم ڪري سگهن ٿا. خاندانن کي گهرجي ته چمڙي ڇلجڻ يا ڪا ٻي علامت ظاهر ٿيڻ جو انتظار ڪرڻ بدران ترت طبي جائزو وٺن.
ڪاواساڪي جي بيماريءَ ۾ رت جي ڪهڙن نتيجن جو عام طور مشاهدو ٿئي ٿو؟
ڪاواساڪي بيماريءَ ۾ عام ليبارٽري نتيجن ۾ CRP يا ESR جو وڌيل هجڻ، اڇن رت جي خلين جو وڌڻ، عمر جي لحاظ کان انيميا، البومين جي گهٽ سطح، ALT جو وڌيل هجڻ، ۽ پوءِ واري مرحلي ۾ پليٽليٽن جو وڌڻ شامل آهن. نامڪمل بيماريءَ لاءِ ضمني حدن ۾ البومين ≤30 g/L، WBC ≥15 × 10⁹/L، ۽ ستين ڏينهن کان پوءِ پليٽليٽ ≥450 × 10⁹/L شامل آهن. اهي نتيجا ڪاواساڪي بيماريءَ لاءِ مخصوص ناهن ۽ انهن جي تشريح معائني ۽ بيماريءَ جي وقتي مرحلن کي نظر ۾ رکندي ڪرڻ لازمي آهي. پيشاب ۾ اڇا رت جا خليا به جائزي ۾ مدد ڪري سگهن ٿا، جيتوڻيڪ اهو رت جي نتيجي بدران پيشاب جو نتيجو آهي.
ڇا نارمل پليٽليٽس يا نارمل ايڪوڪارڊيوگرام ڪاواساڪي بيماري کي رد ڪن ٿا؟
په پهرئين هفتي دوران پليٽليٽس جو معمول تي هجڻ ۽ شروعاتي ايڪوڪارڊيوگرام جو معمول مطابق هجڻ ڪواسڪي بيماريءَ کي رد نٿو ڪري. پليٽليٽس اڪثر ٻئي هفتي دوران وڌن ٿا، ۽ ڪورونري تبديليون ابتدائي اسڪين ۾ ظاهر نه به ٿي سگهن ٿيون. تنهنڪري بيماريءَ جي شروعاتي مرحلي ۾ پليٽليٽس جي ڳڻپ 450 × 10⁹/L کان گهٽ هجڻ تشخيص کي رد نٿو ڪري. لڳاتار بخار يا ڳڻتيءَ جوڳو ڪلينڪي نمونو، تجويز ڪيل علاج ۾ دير ڪرڻ کان سواءِ، ٻيهر جائزي جي گهرج ڪري سگهي ٿو.
How long should a child's fever last before seeking help?
0 ٻار کي 5 ڏينهن تائين بخار رهڻ تي ترت ڪلينڪي جائزو وٺڻ گهرجي، پر سنگين علامتن جي صورت ۾ ان کان اڳ ئي علاج حاصل ڪريو. 3 مهينن کان ننڍڙي ٻار ۾ 38°C يا ان کان وڌيڪ گرمي پد لاءِ ترت طبي جائزو ضروري آهي. ساهه کڻڻ ۾ ڏکيائي، مناسب ردعمل نه ڏيڻ، دٻائڻ سان رنگ نه مٽائيندڙ ريش، جسم ۾ پاڻي جي کوٽ، يا رت جي گردش خراب هجڻ جي صورت ۾ بخار جي مدت کان سواءِ ترت يا هنگامي علاج حاصل ڪرڻ گهرجي. ڪاواساڪي جي 5 ڏينهن واري معيار جو مطلب انتظار ڪرڻ جي هدايت ناهي.
0 ESR ڪواساڪي جي علاج کان پوءِ به ڇو وڌيل آهي؟
ESR can remain high or increase after intravenous immunoglobulin because the infused proteins affect sedimentation. An ESR of 70 mm/hour after treatment therefore does not, by itself, establish treatment failure. Clinicians assess fever, clinical recovery, CRP trends, and cardiac findings instead of relying on post-infusion ESR. Persistent or recurrent fever at least 36 hours after infusion completion requires reassessment by the treating team.
پنهنجي رت جي جاچ جو نتيجو ڪيئن پڙهجي
پنهنجي ليبارٽري رپورٽ اپلوڊ ڪريو ۽ Kantesti جو AI سيڪنڊن اندر هر بائيو مارڪر کي سادي ٻوليءَ ۾ سمجهائيندو. سڄي دنيا ۾ 2 ملين کان وڌيڪ ماڻهن طرفان استعمال ٿيل.
حوالا
- Klein, T., Mitchell, S., & Weber, H. (2026). ڪلينڪل تصديقي فريم ورڪ v2.0 (طبي تصديق وارو صفحو). Kantesti AI طبي تحقيق. ڊي او آءِ
- Klein, T., Mitchell, S., & Weber, H. (2026). AI Blood Test Analyzer: 2.5M ٽيسٽون تجزيو ڪيون ويون | Global Health Report 2026. Kantesti AI طبي تحقيق. ڊي او آءِ
- McCrindle BW et al. (2017). Diagnosis, Treatment, and Long-Term Management of Kawasaki Disease: A Scientific Statement for Health Professionals From the American Heart Association. سرڪيوليشن. ڊي او آءِ پب ميڊ
- Jone PN et al. (2024). Update on Diagnosis and Management of Kawasaki Disease: A Scientific Statement From the American Heart Association. سرڪيوليشن.
- Gorelik M et al. (2022). 2021 American College of Rheumatology/Vasculitis Foundation Guideline for the Management of Kawasaki Disease. Arthritis & Rheumatology.
- 20 لک+تجزيو ڪيل ٽيسٽون
- 127+ملڪ
- 100+ٻوليون
طبي ٽيم بابت
E-E-A-T اعتماد جا سگنل
تجربو
ڊاڪٽر جي نگرانيءَ هيٺ ليبارٽري نتيجن جي تشريح واري عمل جو جائزو.
ماهر
ليبارٽري دوائن جو ڌيان ان ڳالهه تي ته بايو مارڪرز ڪلينڪل حوالي سان ڪيئن رويو ڏيکارين ٿا.
اختيار
ڊاڪٽر ٿامس ڪلائن طبي جائزو ورتو، جنهن ۾ ڊاڪٽر سارا مچل ۽ پروفيسر ڊاڪٽر هانس ويبر جون ڀاڱيداريون شامل آهن.
اعتبار
ثبوتن تي ٻڌل تشريح، جنهن سان خبرداري گهٽائڻ لاءِ واضح پيرويءَ جا رستا موجود هجن.
طبي ترديد
هي آرٽيڪل صرف تعليمي مقصدن لاءِ آهي ۽ طبي مشورو نٿو بڻجي. تشخيص ۽ علاج جي فيصلن لاءِ هميشه ڪنهن قابل صحت فراهم ڪندڙ سان صلاح ڪريو.
شايع ٿيل · ايڊيٽوريل ٽيم سان رابطو ڪريو
Kantesti Ltd پاران شايع ٿيل، انگلينڊ ۽ ويلز ۾ رجسٽرڊ، ڪمپني نمبر. 17090423, ، لنڊن، برطانيه.
